Group items tagged

Being able to access high-quality healthcare at the times you need it most is vital. Regardless of whether this is a simple check-up, a medical review or complex surgery, having a suitable healthcare package designed according to your medical needs will be beneficial in the long run. The NHS has recently come under significant strain. Factors such as an increase in the number of patients, reduced funding and increased life expectancy have led to long waiting times and limited treatments. As a result, more individuals are now seeking private healthcare which, while it may be more expensive, offers faster and more effective treatment. Here we'll discuss some of the main benefits of private healthcare and why it is becoming the ideal choice for healthcare in 2023. Reduced waiting times One of the main issues faced by the NHS is waiting times, with some patients being made to wait up to a year for routine hospital care. Currently, ambulance services and A&E units are under unprecedented pressure and it is estimated that hundreds of deaths each week are associated with admission delays. Understaffing has been a chronic issue in recent years in the NHS and is a major threat to the welfare of patients. This has been one of the major concerns that has led to nurses and ambulance staff taking strike action. As nurses and hospital workers are put under higher strain, they are more likely to make mistakes, which could well lead to patients coming into harm and making a claim. Opting for private healthcare guarantees that you are able to access your appointments, surgeries and treatments much quicker, with some flexibility offered to align with your lifestyle. The capacity to bypass the painfully long waiting times ensures you receive the necessary medical attention much sooner and could prevent the emergence of other health complications.

Despite being the most common genetic disorder in the UK, sickle cell disease (SCD) remains significantly underfunded and underserved compared to other genetic disorders, according to a new report published by the PDA BAME (Black, Asian and Minority Ethnic) Pharmacists' Network. The report also reveals that the disease is poorly understood within the healthcare system, including amongst pharmacists, pharmacy students, and foundation pharmacists in the UK. It emphasises the urgent need for increased awareness, funding, and improved healthcare access for SCD amongst these healthcare professionals. "A lack of education about SCD within the wider healthcare community, including pharmacy, greatly contributes to disparities in care. "Though the importance of SCD education for pharmacists and allied healthcare professionals is acknowledged, it remains unclear whether this topic is adequately addressed within the MPharm curriculum," the report said. The report further noted that in the absence of explicit guidance from the General Pharmaceutical Council (GPhC) or the Pharmaceutical Society of Northern Ireland (PSNI) and without more comprehensive education surrounding SCD embedded within the pharmacy curriculum, pharmacists and future pharmacists may remain "ill-prepared to manage patients with this complex condition." As per the report, sickle cell disease is the most prevalent genetic disorder globally, impacting millions, including around 17,000 people in England.

The Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Dekra to certify medical devices in the UK. Dekra Certification UK has joined the three current UK approved bodies, increasing the UK's capacity to process conformity assessments for medical devices to ensure safe and effective devices reach the UK public. An approved body is an organisation that has been designated by the MHRA to assess whether manufacturers and their medical devices meet the requirements set out in  the UK Medical Devices Regulations 2002. Following an appropriate assessment, the new approved body will issue relevant certification allowing manufacturers to place a UKCA marking on their products before putting them on the market. Dr Laura Squire, chief healthcare quality and access officer at the MHRA, said: "This is a major milestone in our mission to ensure patients across the UK have access to the high-quality medical devices they need to protect their health.

The UK must act swiftly to fend off competition if it wants to build the world's leading life sciences sciences hub, a new report suggests. A year on from the launch of the government's life science vision, the report commissioned by the the Association of the British Pharmaceutical Industry said although achieving the ambition remained feasible, the UK would need an attractive business environment because its competitor countries were becoming more adept at attracting investment. To achieve the ambition of the vision, the PwC-produced report suggested raising pharmaceutical R&D investment in the UK to build a 'stronger manufacturing and research infrastructure', alongside better investment in, access to and uptake of innovative medicines. It said the UK would also need to adopt a renewed approach to the priority healthcare challenges identified in the government's 'Life Science Vision', which would mean cutting the overall burden on health of dementia, cancer, cardiovascular and respiratory disease and mental health. The report quantified the size of the prize if the vision was implemented in full and the UK could emulate the successes of leading EU countries, which included: £68 billion in additional GDP over 30 years, owing to increased R&D investment £16.3 billion additional annual GDP from increased pharmaceutical exports Supporting 85,000 additional jobs Up to 40 per cent decrease in disease burden across the whole UK - for areas like cardiovascular disease, mental health conditions and Cancer. Reduced variation in speed of access to new medicines within three months of licensing for all NHS patients.

In a bid to revolutionise healthcare in the UK, the Reform Party has announced ambitious plans to offer tax incentives to pharmacies. This move comes despite record extra funding in recent years, which has failed to halt a decline in NHS healthcare outcomes. The party argues that while healthcare remains free at the point of delivery, significant reforms are essential to enhance results and eliminate waiting lists. Central to the Reform Party's strategy is a set of critical reforms aimed at addressing NHS challenges within the first 100 days. The implementation of tax breaks for pharmacies is intended to enhance accessibility and alleviate pressure on NHS resources.

Wes Streeting MP has been appointed Secretary of State for Health and Social Care in the new Labour Government. The Ilford North MP will now take on the critical role of overseeing the National Health Service (NHS) and implementing Labour's ambitious health agenda. At the core of the Labour Party's healthcare reform manifesto is enhancing accessibility to primary and community healthcare. This involves implementing a 'Community Pharmacist Prescribing Service,' to empower pharmacists with independent prescribing rights where clinically suitable. This initiative aims to alleviate the strain on GP practices and enhance service accessibility. Additionally, the manifesto proposes piloting Neighbourhood Health Centres, to integrate various healthcare services -such as family doctors, district nurses, and mental health specialists under one roof.

The King's New Year Honours List 2025 has been announced, recognising unsung heroes who have made outstanding contributions to their communities across the UK. Over 1,200 individuals were honoured this year across various sectors, including healthcare, academia, sports, and voluntary service. Michelle Riddalls, CEO of PAGB - the Consumer Healthcare Association, has been awarded an OBE (Officer of the Order of the British Empire) for her exceptional work in advocating for the over-the-counter (OTC) medicines sector. She played a vital role during Brexit negotiations, ensuring continued access to OTC medicines in Northern Ireland and supporting self-care initiatives across the UK. Riddalls has provided oral evidence numerous times to the House of Lords Select Committee on the NI Protocol Bill and actively engaged with the Medicines and Healthcare products Regulatory Agency (MHRA) during the rollout of the Windsor Framework.

The Labour Party's election manifesto, unveiled with a focus on bolstering community pharmacy services and enhancing localised healthcare, has sparked responses from key pharmacy bodies across England. A standout pledge within the manifesto is the commitment to establish a Community Pharmacist Prescribing Service, aimed at granting more pharmacists independent prescribing rights. This initiative is viewed as pivotal in recognising the clinical capabilities of pharmacists and their potential to alleviate pressures within primary care. Additionally, Labour's plan advocates for broader healthcare access improvements, including enabling opticians to directly refer patients to specialist services and expanding self-referral options where suitable. The manifesto also introduces proposals to trial Neighbourhood Health Centres, designed to consolidate various healthcare services under one roof, such as family doctors, district nurses, and mental health specialists.

Global instant logistics leader, Zipline is partnering with UK drone delivery startup, Apian Aero to launch a drone delivery programme of critical medical supplies for the Northumbria Healthcare NHS Foundation Trust. The new service, expected to begin in the autumn of 2024, will see delivery of medical supplies to hospitals, GPs and care homes, using electric, autonomous drones. Zipline announced the partnership on Sunday, and said drone delivery service will help provide timely access to prescription medicines, wound care products, joint replacement implants, and other frequently ordered medical products, which could allow healthcare providers to reduce the number of cancelled procedures, and thus decrease wait times. Also, the expansion of the programme will help in creating local job opportunities in the region, it added.

There is a clear opportunity for community pharmacists and their teams to lead best practice when it comes to supporting the ongoing health needs of older people. As the global population continues to age, the demand for specialised healthcare services tailored to the elderly is rapidly increasing. Community pharmacists, with their accessible locations and frequent interactions with patients, are uniquely positioned to play a pivotal role in addressing this growing need. The ageing population presents a complex set of health challenges, including multiple chronic conditions, polypharmacy, and increased susceptibility to adverse drug reactions. Community pharmacists, armed with their extensive knowledge of medications and their effects, can serve as the first line of defence in managing these issues. By leveraging their expertise, they can implement best practices that not only improve the quality of life for older individuals but also reduce the burden on the broader healthcare system. One of the primary areas where community pharmacists can make a significant impact is in medication management. As people age, they often find themselves taking multiple medications for various conditions. This polypharmacy can lead to dangerous drug interactions, side effects, and compliance issues. Community pharmacists can lead the way in implementing comprehensive medication reviews, ensuring that each patient's drug regimen is optimised for their specific needs and minimising potential risks.

Private healthcare provider CityDoc has partnered with the National Pharmacy Association (NPA) in its bid to widen a "nationwide network of vaccine clinics" to increase footfall to community pharmacies that come onboard. The company says NPA member pharmacies that join the network will have their own dedicated page on the CityDoc website, while benefiting from having online marketing done on their behalf via an extensive Google AdWords campaign and local listings optimisation - all paid for by CityDoc. The participating pharmacies will also have access to their own booking system, marketing materials and access to the latest vaccine and private healthcare information. NPA member Nick Daines, who runs Lifestyle Pharmacy in Bath, said he has partnered with CityDoc for six years and seen "a significant increase in revenue from private services." He added: "The CityDoc partnership has allowed us to establish Lifestyle Pharmacy as a go-to venue for healthcare within Bath. "We have seen significantly increased footfall thanks to our partnership with CityDoc, which in turn has allowed us to grow the NHS and retail aspects of the business."

The rising focus on the "Social" component of Environmental, Social, and Governance (ESG) is prompting UK pharmacies, particularly independent pharmacies, to take a more active role in social responsibility. Beyond just meeting regulatory requirements, pharmacies can strengthen their communities while building trust and supporting business growth by aligning their practices with social initiatives. The importance of social responsibility in ESG Research shows 77% of consumers are motivated to purchase from companies committed to making the world a better place, while 73% of investors state that efforts to improve the environment and society contribute to their investment decisions. As customers, employees and investors increasingly expect businesses to contribute positively to society, the "Social" aspect of ESG is gaining importance. In healthcare, trust, accessibility, and community engagement are essential, giving pharmacies a unique opportunity to lead by prioritising social responsibility. By aligning with community needs and values, pharmacies can positively influence local health outcomes, while strengthening their reputation as trusted healthcare providers.

Eli Lilly's weight-loss medicine Mounjaro, also known as tirzepatide, will be available in the UK within weeks as a four-dose pre-filled injection pen. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the drug to treat adults with type 2 diabetes and for weight management in obese patients. Branded as Mounjaro KwikPen, the injection is to be used together with a reduced-calorie diet and increased physical activity, the regulator said. "The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people's health, is clear. "This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month's treatment, of one dose per week," said Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access.

The Royal College of Nursing (RCN) is calling for scrapping unfair benefit rules for migrant nursing staff, warning that these policies risk triggering a mass exodus from the UK's healthcare workforce. A recent RCN report indicated that two-thirds of internationally educated nursing staff are considering leaving the UK and returning to their country of training due to the high cost of living. The report, which is based on survey responses from more than 3,000 international nursing staff, also revealed that those from overseas are "twice as likely as domestic colleagues to report being in financial difficulty" and are "almost three times as likely as UK counterparts to withdraw from their pension due to the cost of living." It also highlighted the impact of the 'no recourse to public funds' (NRPF) rule, which prevents migrants on temporary visas, such as the Health and Care Worker visa, from accessing essential benefits. In response to this report, the union has urged the government to immediately end these restrictive rules and reduce visa fees, including Indefinite Leave to Remain (ILR) application costs.

Novo Nordisk, the Danish drug manufacturer, has launched Wegovy, a weight-loss drug, in the UK market. This semaglutide injection will be available through specialist NHS weight management services for those who meet the National Institute for Care and Excellence (NICE) criteria or privately through registered healthcare professionals. Novo Nordisk allocated a portion of the available supply of Wegovy for NHS services, while confirming the existing shortage of semaglutide and projecting continued constraints in the foreseeable future. The drug can be obtained through the NHS and is additionally accessible for private purchase at pharmacies in the UK. The pricing for a one-month supply varies, ranging from £73.25 to £175.80, depending on the dosage. "We are committed to expanding treatment options for individuals with obesity and share the Government's goal of improving access to obesity care in areas of high unmet medical need," the company said in a statement. "We are closely monitoring Wegovy demand and collaborating with regulators and providers to ensure access to and continuity of treatment for people living with obesity."

In a groundbreaking move towards modernising healthcare, England's National Health Service (NHS) has successfully implemented digital prescriptions, as reported by the World Health Organization (WHO) in its latest regional digital health report. Since January 2024, patients across England have had access to their prescription information through the NHS App, marking a significant leap in healthcare accessibility and efficiency. With over 33 million registered users, representing 75 per cent of the adult population, the NHS App has become a vital tool in managing healthcare online. The introduction of digital prescriptions allows users to order repeat prescriptions online without the need for a GP visit. This innovation has witnessed a surge in digital requests, with over 3.1 million repeat prescriptions processed monthly.

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects are extensive and significant. Countless individuals in these communities do not have sufficient access to dental care, confronting a harsh reality where a minor toothache can develop into a severe problem. This situation impacts more than just oral health; it also affects general well-being, job prospects, and even self-confidence. Recent studies reveal a startling picture of dental health disparities in these areas. Studies show that individuals residing in rural areas face a higher risk of tooth loss due to untreated decay and gum disease when compared to those living in urban areas with better access to dental care. Children miss school and adults miss work due to preventable dental problems. These statistics paint a bleak portrait of a healthcare gap that demands our immediate attention. Good dental health is not a luxury; it's a fundamental component of a healthy life. It contributes to our overall well-being, playing a role in preventing chronic diseases like diabetes and heart disease. The consequences of neglecting oral health can be devastating, leading to pain, infection, and even systemic health issues.

Over the last few years pharmacy and the role of pharmacy teams has changed dramatically. The introduction of technology and the integration of artificial intelligence (AI) within systems that provide healthcare and support to pharmacies holds great promise; for improving access to health, supporting patient outcomes, and optimising operational efficiency. Currently, the potential use of AI could span the whole of the medicines value chain, from AI-driven drug discovery to personalised medicines and automated dispensing systems. However, the rapid advancement of AI technology does raise several ethical concerns. This article will explore these concerns and how they can be addressed. In previous articles, I have discussed what underpins artificially intelligent machines and the importance of data. Datasets are the foundation on which AI algorithms learn and generate conclusions. The first step to understanding the potential ethical implications of AI across the pharmacy sector is to understand the data that is held within these foundational datasets. Patient privacy and data security AI systems in and outside of the pharmacy sector, which support patient care, rely heavily on vast amounts of medical data (patient medical records, PMR data, etc). However, the collection, storage, and use of such sensitive data can possibly bring significant privacy concerns. GDPR compliance is essential within the UK and ethical questions arise around data ownership, patient consent, and the possibility of data and cybersecurity breaches. As frontline healthcare professionals, we need to be able to support our patients when questions are asked about their data. For example, how can patients be sure their data is used only for its intended purposes? Is anonymised data truly safe from de-identification techniques that could expose private information?

Over the last few years, we've seen the aftermath of Covid-19, with the demand for consumer health products being unprecedented and unpredictable, placing pressure on supply chains and labour market. In turn, the industry has experienced acute shortages across the healthcare sector, placing huge pressure on pharmacists, doctors, nurses, and other healthcare professionals. Europe has an estimated shortage of around 50,000 public-sector doctors[1], which is set to increase in the coming years. While this shortage stems from several complex problems, there is a hidden force that could play a key part in helping to alleviate this burden. That force is the potential of self-care. Encouragingly, last month the UK government recognised the unique role that self-care can play through the introduction of its Delivery plan for recovering access to primary care. Through this, it has pledged to empower patients to manage their own health through several commitments, including improving accessibility to online tools and reclassifying medicines to make formerly prescribed options available over the counter.

The Company Chemists' Association (CCA) has voiced strong support for a recent report from the Tony Blair Institute (TBI), which advocates for the establishment of a 'Digital Health Record' (DHR) for every individual in the UK. The CCA, which was interviewed as part of the report's development, believes that the creation of a DHR could significantly enhance the NHS's efficiency, improve preventative healthcare, and help the health service harness the full potential of artificial intelligence (AI). The TBI report highlights that the current health and care system suffers from fragmented data, with individual records scattered across various providers, including community pharmacies. This siloed approach often hampers the delivery of seamless and effective care. A unified DHR, the report argues, would consolidate all relevant health data into a single, accessible record, ensuring that patients receive timely and appropriate care across the entire healthcare system.